Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

611 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeted siRNA nanocarrier: a platform technology for cancer treatment.
Bäumer N, Tiemann J, Scheller A, Meyer T, Wittmann L, Suburu MEG, Greune L, Peipp M, Kellmann N, Gumnior A, Brand C, Hartmann W, Rossig C, Müller-Tidow C, Neri D, Strassert CA, Rüter C, Dersch P, Lenz G, Koeffler HP, Berdel WE, Bäumer S. Bäumer N, et al. Among authors: hartmann w. Oncogene. 2022 Apr;41(15):2210-2224. doi: 10.1038/s41388-022-02241-w. Epub 2022 Feb 26. Oncogene. 2022. PMID: 35220407 Free PMC article.
SS18-SSX fusion protein-induced Wnt/β-catenin signaling is a therapeutic target in synovial sarcoma.
Trautmann M, Sievers E, Aretz S, Kindler D, Michels S, Friedrichs N, Renner M, Kirfel J, Steiner S, Huss S, Koch A, Penzel R, Larsson O, Kawai A, Tanaka S, Sonobe H, Waha A, Schirmacher P, Mechtersheimer G, Wardelmann E, Büttner R, Hartmann W. Trautmann M, et al. Among authors: hartmann w. Oncogene. 2014 Oct 16;33(42):5006-16. doi: 10.1038/onc.2013.443. Epub 2013 Oct 28. Oncogene. 2014. PMID: 24166495
Deep Sequencing in Conjunction with Expression and Functional Analyses Reveals Activation of FGFR1 in Ewing Sarcoma.
Agelopoulos K, Richter GH, Schmidt E, Dirksen U, von Heyking K, Moser B, Klein HU, Kontny U, Dugas M, Poos K, Korsching E, Buch T, Weckesser M, Schulze I, Besoke R, Witten A, Stoll M, Köhler G, Hartmann W, Wardelmann E, Rossig C, Baumhoer D, Jürgens H, Burdach S, Berdel WE, Müller-Tidow C. Agelopoulos K, et al. Among authors: hartmann w. Clin Cancer Res. 2015 Nov 1;21(21):4935-46. doi: 10.1158/1078-0432.CCR-14-2744. Epub 2015 Jul 15. Clin Cancer Res. 2015. PMID: 26179511 Free article.
PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.
Schmidt LH, Kümmel A, Görlich D, Mohr M, Bröckling S, Mikesch JH, Grünewald I, Marra A, Schultheis AM, Wardelmann E, Müller-Tidow C, Spieker T, Schliemann C, Berdel WE, Wiewrodt R, Hartmann W. Schmidt LH, et al. Among authors: hartmann w. PLoS One. 2015 Aug 27;10(8):e0136023. doi: 10.1371/journal.pone.0136023. eCollection 2015. PLoS One. 2015. PMID: 26313362 Free PMC article.
Blood group antigen A type 3 expression is a favorable prognostic factor in advanced NSCLC.
Schmidt LH, Kuemmel A, Schliemann C, Schulze A, Humberg J, Mohr M, Görlich D, Hartmann W, Bröckling S, Marra A, Hillejan L, Goletz S, Karsten U, Berdel WE, Spieker T, Wiewrodt R. Schmidt LH, et al. Among authors: hartmann w. Lung Cancer. 2016 Feb;92:8-14. doi: 10.1016/j.lungcan.2015.11.019. Epub 2015 Nov 27. Lung Cancer. 2016. PMID: 26775589
Combinatorial effects of doxorubicin and retargeted tissue factor by intratumoral entrapment of doxorubicin and proapoptotic increase of tumor vascular infarction.
Stucke-Ring J, Ronnacker J, Brand C, Höltke C, Schliemann C, Kessler T, Schmidt LH, Harrach S, Mantke V, Hintelmann H, Hartmann W, Wardelmann E, Lenz G, Wünsch B, Müller-Tidow C, Mesters RM, Schwöppe C, Berdel WE. Stucke-Ring J, et al. Among authors: hartmann w. Oncotarget. 2016 Dec 13;7(50):82458-82472. doi: 10.18632/oncotarget.12559. Oncotarget. 2016. PMID: 27738341 Free PMC article.
PD-1 checkpoint blockade in patients with relapsed AML after allogeneic stem cell transplantation.
Albring JC, Inselmann S, Sauer T, Schliemann C, Altvater B, Kailayangiri S, Rössig C, Hartmann W, Knorrenschild JR, Sohlbach K, Groth C, Lohoff M, Neubauer A, Berdel WE, Burchert A, Stelljes M. Albring JC, et al. Among authors: hartmann w. Bone Marrow Transplant. 2017 Feb;52(2):317-320. doi: 10.1038/bmt.2016.274. Epub 2016 Nov 28. Bone Marrow Transplant. 2017. PMID: 27892950 Clinical Trial. No abstract available.
Targeting Ewing sarcoma with activated and GD2-specific chimeric antigen receptor-engineered human NK cells induces upregulation of immune-inhibitory HLA-G.
Kailayangiri S, Altvater B, Spurny C, Jamitzky S, Schelhaas S, Jacobs AH, Wiek C, Roellecke K, Hanenberg H, Hartmann W, Wiendl H, Pankratz S, Meltzer J, Farwick N, Greune L, Fluegge M, Rossig C. Kailayangiri S, et al. Among authors: hartmann w. Oncoimmunology. 2016 Oct 28;6(1):e1250050. doi: 10.1080/2162402X.2016.1250050. eCollection 2017. Oncoimmunology. 2016. PMID: 28197367 Free PMC article.
611 results